Related references
Note: Only part of the references are listed.Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine
Chiao-Hsu Ke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Skin cancer: Primary, secondary, and tertiary prevention. Part I
Mariana Perez et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe et al.
EUROPEAN JOURNAL OF CANCER (2022)
Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma
Jielin Rong et al.
Aging-US (2022)
A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma
Jia'nan Zhong et al.
LIFE SCIENCES (2022)
Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma
Yujian Xu et al.
FRONTIERS IN SURGERY (2022)
CD8+ T cell differentiation and dysfunction in cancer
Mary Philip et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Skin cancer: Primary, secondary, and tertiary prevention. Part I
Mariana Perez et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Immune checkpoint inhibitors in melanoma
Matteo S Carlino et al.
LANCET (2021)
Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols
Shanrong Zhao et al.
RNA (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
Mairead G. McNamara et al.
CANCER TREATMENT REVIEWS (2020)
Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma
Li-Xin Wang et al.
MEDICAL SCIENCE MONITOR (2019)
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
Umang Swami et al.
JOURNAL OF ONCOLOGY (2019)
Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor
Sourav Paul et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
Meng Cao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Tavi Nathanson et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine et al.
CLINICAL CANCER RESEARCH (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair
Timothy Budden et al.
ONCOTARGET (2016)
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen et al.
JAMA ONCOLOGY (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information
Kaushala Jayawardana et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa-Montoya et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
pROC: an open-source package for R and S plus to analyze and compare ROC curves
Xavier Robin et al.
BMC BIOINFORMATICS (2011)
Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis
Frederic Reynier et al.
PLOS ONE (2011)
Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Goran Jonsson et al.
CLINICAL CANCER RESEARCH (2010)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
